Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
SAB Biotherapeutics (SABS) Stock Price & Analysis
45 Followers
SABS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.37 - $1.81
Previous Close$0.96
Volume90.64K
Average Volume (3M)1.36M
Market Cap
$48.38M
Enterprise Value$40.78M
Total Cash (Recent Filing)$13.06M
Total Debt (Recent Filing)$5.46M
Price to Earnings (P/E)-1.7
Beta1.92
Next Earnings
Aug 09, 2023EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding50,394,262
10 Day Avg. Volume53,681
30 Day Avg. Volume1,360,313
Standard Deviation0.35
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)82.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue70.18
Enterprise Value/Gross Profit1.71
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$3.50Price Target Upside264.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
SAB Biotherapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $0.36 and its highest was $1.81 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
Currently, no data Available
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Aug 09, 2023 which is in 62 days.
How were SAB Biotherapeutics’s earnings last quarter?
Currently, no data Available
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -$0.14.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 50,397,762 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Among the largest hedge funds holding SAB Biotherapeutics’s share is Fir Tree Inc.. It holds SAB Biotherapeutics’s shares valued at 4M.
---
SAB Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (264.58% Upside)
$3.50 (264.58% Upside)
Hedge Fund Trend
Decreased
By 144.0 Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.66%
12-Months-Change
Fundamentals
Return on Equity
-82.49%
Trailing 12-Months
Asset Growth
-36.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SAB Biotherapeutics
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
---
Top 5 ETFs holding SABS
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold SABS. The ETFs are listed according to market value of SABS within the ETF
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
SELLAS Life Sciences Group
―
Galera Therapeutics
―
MEI Pharma
―
Biora Therapeutics
―
Exagen
―
---